Lansoprazole Laboratorios Liconsa S.A

Lansoprazole, the active ingredient in Lansoprazole Laboratorios Liconsa S.A, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is used to manage conditions such as gastro‑esophageal reflux disease, peptic ulcer disease and in Helicobacter pylori eradication protocols.

GNH USA supplies Lansoprazole Laboratorios Liconsa S.A as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal conditions.

Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. Peptic ulcer disease: facilitates ulcer healing by decreasing gastric acidity. Erosive esophagitis: promotes mucosal recovery and symptom relief. Helicobacter pylori eradication: used in combination therapy to improve bacterial clearance.

Lansoprazole may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild, transient headache reported in many patients. - Diarrhea: loose stools occurring during early therapy. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of queasiness without vomiting.

Serious or Rare Side Effects: - Severe allergic reactions: anaphylaxis or angioedema requiring immediate medical attention. - Low magnesium levels: hypomagnesemia with prolonged use, may cause muscle cramps or cardiac arrhythmia. - Clostridioides difficile infection: increased risk of severe colitis, especially with long‑term therapy.

Before initiating therapy, consider the following precautions.

Assess renal function: adjust use in severe renal impairment. Monitor magnesium levels: prolonged therapy may cause hypomagnesemia. Avoid abrupt discontinuation: may cause rebound acid hypersecretion. Use with caution in elderly: higher fracture risk with long‑term use. Store at room temperature: keep in original container, protect from moisture.

Lansoprazole can affect the pharmacokinetics of several medicines.

Major Interactions (Avoid): - Ketoconazole: reduced absorption and efficacy of ketoconazole. - Atazanavir: decreased antiretroviral plasma concentrations. - Clopidogrel: reduced activation leading to diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation. - Digoxin: may raise serum digoxin levels, watch for toxicity. - Methotrexate: increased risk of toxicity, especially at high doses.